Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy ...

Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive ...

The seventh LP from the Manchester rockers, it’s the band’s first release of new material in four years, but follows little more than a year after they secured their first-ever chart-topper ...

Forget the walk-off grand slam off the bat of a hobbled Freddie Freeman. Forget the questionable bullpen decisions, such as using Nestor Cortes in a high-leverage spot with the game on the line in ...

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found. The ...